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doi:10.1016/j.pedneo.2011.08.002Rett syndrome (RTT), a neurodevelopmental condition characterized by delayed-onset loss of
spoken language and the development of distinctive hand stereotypies, affects approximately
1 in 10,000 live female births. Clinical diagnosis has been based on symptoms such as loss of
acquired purposeful hand skills, autistic behaviors, motor dysfunctions, seizure disorders,
and gait abnormalities. RTT is a genetic disease and is caused almost exclusively by mutations
in the X-linked gene, MECP2, to produce a phenotype that is thought to be primarily of neuro-
logical origin. Clinical reports show RTT patients to have a smaller brain volume, especially in
the cerebral hemispheres, and alterations in various neurotransmitter systems, including
acetylcholine, dopamine, serotonin, glutamate, substance P, and various trophic factors.
Because of its monogenetic characteristic, disruption of Mecp2 is readily recapitulated in mice
to produce a prominent RTT-like phenotype and provide an excellent platform for under-
standing the pathogenesis of RTT. As shown in human studies, Mecp2 mutants also display
subtle alterations in neuronal morphology, including smaller cortical neurons with a higher-
packing density and reduced dendritic complexity. Neurophysiological studies in Mecp2-
mutant mice consistently report alterations in synaptic function, notably, defects in synaptic
plasticity. These data suggest that RTT might be regarded as a synaptopathy (disease of the
synapse) and thus potentially amenable to rational therapeutic intervention.
Copyright ª 2011, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.for Neuroscience and
Glasgow G12 8QQ, United
ow.ac.uk (S.R. Cobb).
an Pediatric Association. Publish1. Introduction
Rett syndrome (RTT; MIM 312750) was first identified by Dr
Andreas Rett in 1966, after he observed 22 patients with
similar unique symptoms.1 The constellation of features
that represent RTT became more widely recognized ased by Elsevier Taiwan LLC. All rights reserved.
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larger studies by Dr Hagberg et al.2 In 1999, Amir et al3
discovered the genetic basis of RTT (>95% of cases of
classical RTT to date) to be mutations in the gene MECP2,
thus successfully linking the fields of genetics and
neurology. The discovery of MECP2 as the primary cause of
RTT opened into another field, that of molecular biology.
Some years earlier, Dr Bird and colleagues4 identified
MeCP2 (methyl-CpG binding protein 2) as a novel protein
that binds to methylated CpG dinucleotides within the
mammalian genome. Methylation of CpGs is associated with
gene silencing and alterations in chromatin structure.
Although the exact function of MeCP2 is still not known, it is
an abundant nuclear protein and is considered likely to
regulate gene expression whether through the silencing or
activation of specific genes or through more global regula-
tion (e.g. dampening) of transcriptional processes.5e7
An important feature in the etiology of RTT is the fact
that MECP2 is located on the X chromosome, Xq28.8 Most
mutations are sporadic and rarely inherited. Moreover,
mutations in males typically result in severe infantile
encephalopathy because of complete absence of functional
MeCP2. In contrast, females are heterozygous for the
mutation with, because of X chromosome inactivation,
approximately one-half of the cells expressing the mutant
MECP2 allele but with the other half expressing a functional
allele. Thus, RTT is a disease that is almost exclusively seen
in females.
Because of the monogenic characteristic of RTT (i.e.
single gene disorder), several Mecp2 knockout models have
been generated in mice and other species for investigating
RTT-like pathologies and for identifying and testing
therapies.9e13 Such animal studies are important changing
the way we view neurodevelopmental conditions, including
the tractability of such disorder. The traditional view that
abnormalities in brain development will produce aberra-
tions in the nervous system and result in irreversible
neurological and psychiatric features has been challenged.
Specifically, a number of studies in animal disease models
ranging from Down’s syndrome,14,15 tuberous sclerosis,16e18
fragile X syndrome,19,20 Angelman syndrome,21 as well as
RTT10 have demonstrated an unexpected propensity for
phenotypic reversal, even in adult mice.22 As yet, few of
these results have yet been translated to the clinic. The
current short review summarizes the main clinical features
and genetics of RTT before considering the recent advances
in animal model studies in aiming to understand the path-
ogenesis of RTT and identifying and testing rational thera-
peutic strategies, thus filling the gap between clinical
practice and basic research in RTT.2. Clinical Features
RTT is a predominantly neurological disorder and a primary
cause of severe mental retardation in girls with an inci-
dence of approximately 1 in 10,000 female births.23
Patients with RTT appear to develop normally up to 6e18
months of age. They typically achieve normal neuro-
developmental milestones, from gross and fine motor
functions to social communication skills. The head
circumference of Rett girl is normal at birth; however, itbegins to decelerate in its growth at 2e3 months of age.24
Distinctive aspects contributing to the diagnosis include
developmental regression, with accompanying loss of hand
skills, mobility skills, and speech and stereotypic hand
movements. As the syndrome progresses, social withdrawal
and loss of language become apparent with features remi-
niscent of autism.25 The onset of mental deterioration is
accompanied by loss of motor coordination and the devel-
opment of ataxia and gait apraxia. Associated features such
as microcephaly, respiratory/autonomic abnormalities,26
seizures, scoliosis, growth deficits and early hypotonia are
very prevalent.
Among these symptoms, the most significant one to
pediatrician is seizure disorder, which ranges from simple
convulsion to intractable epilepsy.27 Neurophysiologic
evaluations show cortical hyperexcitability on the electro-
encephalogram (EEG), which represents a loss of expected
developmental features and the occurrence of rhythmic
slow activity, primarily in the frontal-central regions.
However, most events presumed to be seizures are without
EEG correlation during video-EEG recording.28 Other asso-
ciated abnormalities during the postregression phase
include teeth grinding, night laughing or crying, screaming
fits, low mood, and anxiety episodes elicited by distressing
external events.29 Most girls with RTT lose mobility and are
often wheelchair-bound during the teenage years. Impair-
ment of the autonomic nervous system in RTT is suggested
by an increased incidence of long QeT intervals during
electrocardiographic recordings and it can contribute to
the higher incidence rate of sudden unexpected death in
RTT patients. Other autonomic abnormalities include
hypotrophic cold blue feet; severe constipation; oropha-
ryngeal dysfunction; and cardiac abnormalities, including
tachycardia and sinus bradycardia. Even with high risk of
sudden death because of respiratory and cardiac dysfunc-
tions, several patients survive till the 6th or 7th decade of
life with limited mobility.303. Genetic Background
RTT cases are usually the result of dominantly acting,
sporadic mutations in the X-linked gene MECP2, which
encodes methyl-CpG-binding protein 2 (MeCP2).3 MeCP2 is
expressed quite widely throughout the body, with notably
high expression in postnatal neurons.12,31,32 However, the
question remains why disruption of a ubiquitously expressed
protein results in a predominantly neurological pheno-
type.32 Most pathogenic mutations in MECP2 cause RTT in
heterozygous females, whereas mutations leading to other
phenotypic outcomes are also known.33 Because most RTT
cases are sporadic, it was difficult to map the disease locus
by traditional linkage analysis; instead, using information
from rare families, Xq28 region was identified and subse-
quent screening of candidate genes in RTT patients revealed
mutations in MECP2.3 Boys inheriting a mutant MECP2 allele
are much more severely affected, presenting with infantile
encephalopathy and usually not surviving infancy. Because
most MECP2 mutations leading to RTT involve loss of func-
tion of the mutant allele, RTT can be modeled using gene
knockout mice that recapitulate many of the key clinical
signs that characterize RTT in humans.10,11
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regions of DNA enriched with methylated CpG regions.34
Containing a methyl-CpG binding domain and a transcrip-
tional repression domain,35,36 MeCP2 was classically consid-
ered a methylation-dependent transcriptional repressor.37
However, other studies suggest additional or alternative
roles, including an enhancer of transcription,6 a global
regulator of chromatin structure,38 or a global dampener of
transcriptional noise.7
MeCP2 is expressed in a range of tissues but is especially
abundant in postmitotic neurons. Mice lacking MeCP2 in
neurons show overt RTT-like symptoms, whereas mice in
which the expression of MeCP2 is driven in neurons alone
are reported to show a normal phenotype.39 Although
MeCP2 is present at low levels in astrocytes and MeCP2
deficiency in these cells may confer subtle noncell auton-
omous actions on neuronal phenotype,40,41 a body of
evidence points to the overt RTT-like symptoms being due
mainly to MeCP2 deficiency in the nervous system and
neurons in particular.
4. Neuropathology in RTT Patients
The average 1-year-old infant brain weight in RTT patients
is 900 g. The weight of the RTT brain is significantly less
than that of the brain of age-matched controls in autopsy
studies.42 Observation of MeCP2 expression showed it
primarily distributed in post-mitotic neurons.43 The weight
of the Rett brain does not decrease significantly with age,
so atrophy does not account for the small brain.42 Instead,
RTT is characterized by lack of brain growth, which is not
generalized because some structures such as the cerebral
hemispheres are affected more than other structures such
as the cerebellum.42 Alterations in brain volume mainly
occur in prefrontal, posterior frontal, and anterior
temporal regions, with preservation in the posterior
temporal and posterior occipital regions.44,45
Neurochemical studies based on RTT patient data are
relatively limited. Nevertheless, cerebrospinal fluid and
brain tissues have been analyzed with respect to levels of
various transmitters, receptors, and additional trophic
factors. Abnormalities have been reported in most systems,
including in acetylcholine,46e48 dopamine,49e53 sero-
tonin,54,55 glutamate,56,57 substance P,58,59 and nerve
growth factor.60,61 The age of the patient with RTT52 and
the severity of the symptoms53 influence measurements.
The reduced levels of acetylcholine and cholinergic
markers42 is one of the most consistent findings.47 In terms
of therapeutic potential, much interest has surrounded the
monoamine systems (see in the following sections).
5. Animal Models of RTT
Several genetic mouse models of RTT have been developed
through interruption of murine Mecp2, and these models
accurately recapitulate the cardinal signs that characterize
RTT in humans.9e12,39 RTT models are proving invaluable in
helping to understand the underlying pathology and neuronal
dysfunction in RTT as well as providing insights into the
pathophysiology of neurodevelopmental disorders more
generally.Mecp2-null male mice develop motor impairment,tremor, breathing abnormalities, and limb stereotypies.9e11
In most of the models, the null males demonstrate appar-
ently normal early development before the onset of overt
signs at about 6 weeks of age, and progression is usually fairly
aggressive, with death at about 16e20 weeks. Females
heterozygous for Mecp2 show a more delayed onset of
symptoms. The symptom severity increases over a period of
weeks to months, as in human females, these stabilize and
the mice show an apparently normal lifespan.
Three RTT models have been widely used, the first one is
the Jaenisch model,11 which is generated from the cre-lox
recombination system in which exon 3 is deleted. In
males normal development is noted before 5 weeks
following which mice develop nervousness, body trembling,
piloerection, and occasional breathing abnormalities. Mice
typically experience weight loss at 8 weeks and most die by
10 weeks. Reduced brain weight and neuronal size in
hippocampus, cerebral cortex, and cerebellum are
observed and have been reported. The second model is the
Bird model,9 which was generated by deletion of exons 3
and 4 of Mecp2 in embryonic stem cells to produce
a complete null in terms of the production of MeCP2
protein. Hemizygous males are normal till 3e8 weeks, later
develop stiff uncoordinated gait, hindlimb clasping, irreg-
ular breathing, and uneven teeth wear. Symptoms progress
rapidly after 10 weeks with weight loss and death at around
12e16 weeks. In contrast, the heterozygous females
develop inertia and hindlimb clasping at around 3 months
and breathing abnormalities (irregular breathing patterns)
and decreased mobility after 6 months. They survive longer
than males and are fertile. The Mecp2308/y model12 is
a milder model and was generated by insertion of a trun-
cating Mecp2 mutation. A stop codon (at position 308)
produces a protein that is truncated yet retains the methyl-
CpG binding domain, transcriptional repression domains,
and nuclear localization signal motif. Males appear normal
till 6 weeks and later develop tremors, motor impairment,
hypoactivity, anxiety behavior, seizures, kyphosis, and
stereotypic forelimb motions. Survival is much longer than
MeCP2 null models with males living to 10 months and being
fertile. Females also survive and have milder symptoms
than seen in the null (complete absence of protein) models.
Most RTT model studies have focused on global deletion
or truncation of Mecp2.9,11,12,62,63 Behavioral studies in
these mice have revealed altered gait and motor defects,
including hypoactivity, paw stereotypies, and balance and
swimming impairments. Such mice also display an anxiety
phenotype, including reduced exploration, increased thig-
motaxis (movement toward or away from mechanical
stimulus), and altered plus and zero maze behavior. Motor
dysfunction limits the application of certain cognitive tests,
but impairments in fear conditioning and novel object
recognition have been reported.62,63 In the Mecp2308/y
model, which generates truncated MeCP2 and displays
significantly milder symptoms, mice show impairments in
hippocampal-dependent spatial memory as well as social
memory.64
Like in RTT patients, Mecp2-mutant mice have smaller
cortical neurons packed at a higher density than their wild-
type littermates.11,63,65 Moreover, pyramidal neurons in the
cortex65 as well as in hippocampal CA3 region, and granule
cells of the dentate gyrus show reduced dendritic
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show a disorganized olfactory neuroepithelium indicative of
delayed terminal differentiation.66 However, dendritic
branching in Layers III and V pyramidal neurons of the
frontal cortex of male Mecp2308/y mice was comparable
with that in the controls.64 In the Bird model, pyramidal
neurons from the somatosensory cortex of 6-week-old mice
show lower spine densities compared with wild-type
controls.67 Newly generated granule cells in the dentate
gyrus of 8-week-old Jaenisch model mutant mice also show
impaired dendritic spine density and distribution.68 In
female heterozygous mice, the onset of this dendritic spine
phenotype is delayed and more severe in Mecp2-lacking
neurons than in Mecp2-expressing neurons, suggesting both
cell autonomous and non-cell autonomous effects.69 The
intensity of PSD-95 (an abundant postsynaptic protein) is
also lower in Layer V pyramidal neurons of the motor cortex
of MeCP2-null mice.70 As to the presynaptic terminals, the
motor cortex of Bird model mice show defects in axonal
fasciculation.71 Moreover, the intensity of VGLUT1 (a
presynaptic protein) is lower in the dendritic region of the
hippocampal CA1 region from MeCP2-null mice; however,
the postsynaptic dendritic marker MAP-2 was not different,
the authors interpreted that Mecp2 deletion caused
a reduction in the number of mature synapses in area CA1,
consistent with their results from dissociated neuronal
cultures.72
6. Neurophysiological Studies and Synaptic
Plasticity
At the cellular level, studies in mice show subtle changes in
neuronal electrical properties within cortical areas73,74 and
more pronounced changes in other regions such as the brain
stem and locus ceruleus.75,76 Overt changes in synaptic
function include reduced synaptic plasticity10,64,77,78
and changes in basal inhibitory and excitatory synaptic
transmission.73,74,76,78e80 Anatomical studies have shownFigure 1 Symptomatic Mecp2-mutant mice show deficits in bot
showing onset and progression of phenotypic (RTT-like) signs in ma
symbols) invariably score 0. Note that Mecp2-mutant mice develop
increasing over the subsequent 10e12 weeks. (B) Bar plot shows
frequency stimulation. Note that in wild-type mice (Severity score
lative enhancement in response to second and subsequent high-fre
show reduced propensity to produce further long-term enhancem
tetanic potentiation) are also progressively impaired as Mecp2-m
permission. RTTZ Rett syndrome.changes in synaptic connectivity and neuronal
structure,72,81e83 whereas at the network level, there are
changes in network excitability.79,84 Interestingly, synaptic
plasticity (activity-dependent changes in the strength of
synaptic communication) appears normal in young Mecp2-
mutant mice10,77,85 but shows impairment when tested in
older mice on onset of overt RTT-like signs.10,77 Moreover,
the degree of impairment appears to correlate with the
severity of the RTT-like neurological phenotype (see
Figure 1). The precise mechanisms underlying the involve-
ment of MeCP2 in regulating morphological and functional
aspects of synaptic signaling remain to be identified.
However, synaptic plasticity deficits are one of the most
consistent findings and may provide important insights into
RTT-like pathogenesis as well as serving as a target system
for therapeutic interventions.
7. Therapeutic Approaches
It appears that lack of functional MeCP2 results in a nervous
system primed to malfunction at a critical point during
postnatal brain development. However, function can be
restored (including normal plasticity) to a large degree by
the reintroduction of MeCP2.10 In the study by Guy et al,10
endogenous Mecp2 was silenced by insertion of a lox-stop
cassette allowing the mice to develop symptoms (and
plasticity deficits) before MeCP2 could be reintroduced into
the brain by pharmacological reactivation of the gene. This
reactivation resulted in a pronounced improvement in
neurological signs and reduced mortality in the mice.
Similar strategies to reintroduce or rebalance MeCP2 levels
have been adopted by other groups using different genetic
approaches and these studies have demonstrated
improvements in motor function and a reversal of brain
weight and neuronal morphology deficits.39,86,87 Another
genetic strategy has been to overexpress the brain-derived
neurotrophic factor (BDNF, a potent modulator of synaptic
plasticity/function that is dysregulated in MeCP2-mutanth long-term and short-term synaptic plasticity. (A) Time plot
le Mecp2-mutant mice (orange symbols). Wild-type mice (black
overt signs from around 5 weeks of age, with the severity score
long-term plasticity following repeated (15 min interval) high-
Z 0) the long-term plasticity level shows a robust and cumu-
quency stimulation, whereas symptomatic Mecp2-mutant mice
ent. (C) Bar plot showing levels of short-term plasticity (post-
utant mice develop RTT-like signs. From Weng et al103 with
Rett syndrome, from clinics to animal studies 313mice), which again reverses signs such as locomotor defi-
cits.88 Although none of these studies represent a thera-
peutic strategy that can be applied to human patients, they
nevertheless demonstrate the concept of phenotypic
reversibility in mouse models of RTT and suggest that the
Mecp2-mutant mice represent a viable platform for testing
future pharmacological and genetic strategies that can be
translated for clinical use.
The most obvious strategy in RTT is one of gene therapy.
This approach has been successful in disorders such as
thalassaemia,89 sickle cell disease,90 cystic fibrosis,91 and
some cancers92e95 but the application of gene therapy to
CNS disorders is a particular challenge. Although concep-
tually straightforward, RTT being a monogenic disorder, the
application of gene therapy in RTT is likely to be prob-
lematic on numerous counts. For instance, it is likely to be
necessary to express MeCP2 in the correct cell types and at
the correct levels because overexpression of MeCP2 is also
known to be detrimental.96 A related complication is that
females with RTT have a mosaic expression of MeCP2 with
cells expressing the mutant allele and other cells express-
ing the normal allele and producing functional protein.97 It
is possible that a targeted strategy would be required
whereby the transgene was activated only in the “mutant”
cells and avoiding overexpression in the cells with the
“healthy” allele, which are presumably functioning nor-
mally. This is an active current area of research but there is
relatively little published literature as yet. Using lentiviral
delivery of Mecp2 driven by the endogenous Mecp2
promoter, Rastegar et al98 achieved natural expression
patterns of MeCP2 and concomitant reversal of dendritic
maturation phenotypes in vitro but this approach has not
yet been tested in vivo.
In contrast to the limited gene therapy literature,
a significant number of studies have investigated pharma-
cological interventions in models of RTT. Several modula-
tors of synaptic function/plasticity have been tested,
including the AMPA receptor modulator CX546, the insulin-
like growth factor-1 tripeptide, the monoamine reuptake
inhibitor desipramine, and the Alzheimer drug memantine.
In addition to the pharmacological strategies targeting
neuronal mechanisms downstream of the MeCP2 deficiency,
another approach is to target the MeCP2 mutation itself.
This may be applied to specific but common mutations in
MeCP2 leading to premature stop codons. Gentamycin,
a widely used antibiotic agent, has this capacity and can
provide modest (10e22%) read-through of common
nonsense mutations in Mecp2-mutant transfected HeLa
cells.99 Whether this approach can be successfully applied
in vivo or indeed in the clinic remains to be established.
The studies focusing on AMPA receptor modulators (the
ampakine CX546) are based on the fact that levels of BDNF
are considered to be regulated by MeCP2 binding100 and
that aberrant levels of BDNF have concomitant effects on
neurite outgrowth and synaptic maturation and mainte-
nance. Mice treated with daily dosing of CX546 showed
enhanced levels of BDNF and an improvement in the
breathing phenotype (irregular breathing patterns), which
is a prominent feature of RTT patients and seen in Mecp2-
mutant mice.101
Another drug targeting glutamate receptors (and
possibly cholinergic systems also) is the Alzheimer’s drugmemantine. This drug has recently been shown to be
effective in other neurodevelopmental disorder models102
and is well known to be effective in alleviating synaptic
plasticity deficits. Weng et al103 recently reported
a synaptic plasticity saturation effect in the hippocampus
of Mecp2-mutant mice and that impairment in both short-
and long-term forms of synaptic plasticity can be partially
reversed by memantine application in vitro when applied at
clinically relevant concentrations. However, administration
of memantine to Mecp2-mutant male mice was ineffective
at preventing the onset of RTT-like signs and survival.
Nevertheless, it remains to be tested whether memantine
can afford cognitive benefits in females with a milder and
stable RTT phenotype and mimic the human genotype.
In addition to BDNF (via ampakines), another growth
factor that has received attention is IGF-1, which is a well-
known regulator of synaptic maturation and plasticity. The
activity of IGF-1 is regulated by a range of IGF-binding
proteins. One of these, IGFBP3, has a binding site for the
MeCP2104 and MeCP2-null mice and RTT patients express
aberrantly high levels of this protein, which would be ex-
pected in turn to inhibit IGF-1 signaling.105 An active tri-
peptide fragment of IGF-1 has been shown to enhance
lifespan, improve locomotor function, and breathing
pattern and heart rate abnormalities in MeCP2-null mice.70
At the cellular level, reversed structural and cortical plas-
ticity deficits were also observed following IGF-1 tripeptide
treatment70 and clinical trials using recombinant IGF-1 are
now underway.
For some time, there has been an interest in monoamine
systems with respect to RTT. There are consistent reports
that levels of monoamine markers are reduced in the RTT
brain and in MeCP2-null mice.49,50,53,106 To counter these
deficits, drugs such as desipramine (an inhibitor of mono-
amine uptake) have been tested in MeCP2-null mice.107,108
Repeated administration of desipramine improves
breathing and prolongs lifespan in RTT mice and at
a cellular level, reverses the depletion in brain stem tyro-
sine hydroxylase.107
8. Conclusion
It has been more than 40 years since girls with Rett
phenotype were first reported1 and the last decade has seen
a rapid escalation in basic research. It is clear that defi-
ciency of MeCP2 has a multiple downstream consequences
and that a fuller understanding of the molecular actions of
MeCP2 will reveal new strategies for targeting the disorder.
However, genetically engineered mouse studies have amply
demonstrated the concept of phenotypic reversibility and
progress is being made on a number of fronts to find ways of
reversing synaptic, functional, and behavioral aspects of
RTT. It is not unreasonable to expect that some of these
approaches will see rational interventions move from labo-
ratory bench to bed in the coming years.
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